 iStockAnalyst (press release) | Abbvie, Inc: Steady Humira = Steady ABBV iStockAnalyst (press release) Daclizumab for Relapsing Remitting Multiple Sclerosis: A Phase III candidate. Effective but well behind very good new oral options (e.g. Novartis' Gilenya) that have similar efficacy. However, Daclizumab could be even more convenient as a once-monthly ... |
